Crohn’s & Colitis Foundation, Genedata Collaborate on Precision Medicine

Crohn’s & Colitis Foundation, Genedata Collaborate on Precision Medicine
0
(0)

Genedata and the Crohn’s & Colitis Foundation completed a project aimed at advancing precision care for Crohn’s disease patients.

Genedata, a biopharmaceutical research and development software company, worked with foundation investigators and clinicians to integrate and study multi-omic and clinical data culled from patients with Crohn’s, which, along with ulcerative colitis, is among the most common forms of inflammatory bowel disease (IBD).

The data will be used to identify the biomarkers that can be the most useful in evaluating, within five years of IBD diagnosis, a person’s risk of developing disease complications that require surgery.

“Crohn’s disease is a chronic, often debilitating disease, for which there is currently no cure,” Andres Hurtado-Lorenzo, PhD, the foundation’s senior director of translational research, said in a press release. “Despite several treatment options, currently we lack predictive tests to determine the optimal treatment strategy early in the disease process, when the opportunity to improve outcomes is greatest.”

“There is a significant unmet need to advance new diagnostic tools to enable precision medicine approaches and to optimize patient care according to the severity of the disease course,” he said.

The foundation sought help with leveraging abundant clinical and molecular data. Multi-omics is an approach in which multiple datasets (such as genes or protein profiles) are combined and analyzed for new associations.

Genedata used its precision medicine software platform, Genedata Profiler, to provide data analysis that could advance biomarker research efforts. Biomarkers are useful in predicting disease trajectory, which is crucial to personalized treatment plan development.

“We decided to implement cutting-edge data analysis methods to integrate clinical and genomic data from patients, as a strategy to advance our biomarker research efforts,” Hurtado-Lorenzo said. “We are pleased to have found in Genedata a trusted and reliable partner who provided us with expert knowledge in big multi-omic data analysis.”

“This collaboration is helping us accelerate our search for precision biomarkers to prognosticate disease course and to guide early and effective personalized treatment decisions in Crohn’s disease patients,” he said.

Othmar Pfannes, CEO of Switzerland-based Genedata, said it’s difficult to analyze clinical data combined with rapidly growing, voluminous and complex multi-omic information.

“Our data science services, together with our Genedata Profiler platform, is set up to address this challenge and to enable our partners to make data-informed decisions on a per-project basis without having to build their own data infrastructure or hire data scientists,” he said. “We’re proud that our expertise has been helpful to the Crohn’s & Colitis Foundation.”

The Crohn’s & Colitis Foundation has the world’s largest repository of IBD patient data from institutions around the world. More than 3 million U.S. residents live with the disease.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 455
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Total Posts: 34
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • takeda research collaboration
  • CT-SCOUT app studied
  • gut microbes
  • Genedata

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?